HeartSciences’ MyoVista® signal processed ECG (spECG™) Cardiac Testing Device is breakthrough technology in electrocardiography designed to assist in the early detection of heart disease. MyoVista spECG™ technology is focused on closing the diagnostic gap related to identifying patients having an elevated risk of a cardiac adverse event. Patented signal processing methods using wavelet mathematics provide new information related to energy in the acquired ECG signal.

Proprietary informatics characterize energy related information and metrics, providing new data that is used in  assisting in the detection of repolarization abnormalities (T-wave abnormalities).